发布求助
文献互助 智能选刊 最新文献

Advances in Cancer Research最新文献

筛选
英文 中文
Strategies to mitigate the toxicity of cancer therapeutics. 减轻癌症治疗药物毒性的策略。
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2022-03-21 DOI: 10.1016/bs.acr.2022.02.006
Adriana M Kahn, Kim R M Blenman, Steve T Sonis, Maryam B Lustberg
{"title":"Strategies to mitigate the toxicity of cancer therapeutics.","authors":"Adriana M Kahn,&nbsp;Kim R M Blenman,&nbsp;Steve T Sonis,&nbsp;Maryam B Lustberg","doi":"10.1016/bs.acr.2022.02.006","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.02.006","url":null,"abstract":"<p><p>Cancer therapeutics are dynamically evolving, and include traditional chemotherapy and hormone therapy, as well as more recently developed treatment modalities, such as tyrosine kinase inhibitors, monoclonal antibodies and the revolutionary approach based on immune checkpoint inhibition. These regimens are unfortunately not free of adverse events, and patients with cancer are a susceptible population experiencing a myriad of disease and treatment toxicities combined. In this review, we present the latest overview of the management of the most common systemic cancer treatment symptoms and the science of symptom management supporting these strategies. We discuss cancer-related cognitive impairment, ocular toxicity, ototoxicity, oral mucosal toxicities, gastrointestinal toxicities, renal toxicity, aromatase inhibitor-induced musculoskeletal symptoms, chemotherapy-induced peripheral neuropathy, and immunotherapy-induced autoimmunity derived from systemic therapies for cancer. In summary, we review the future directions and ideal goals of symptom science research in order to benefit patients utilizing a comprehensive individualized approach.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"215-244"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40577648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface. 前言。
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/S0065-230X(22)00067-7
David A Gewirtz, Paul B Fisher
{"title":"Preface.","authors":"David A Gewirtz,&nbsp;Paul B Fisher","doi":"10.1016/S0065-230X(22)00067-7","DOIUrl":"https://doi.org/10.1016/S0065-230X(22)00067-7","url":null,"abstract":"","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"xi-xii"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40577650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface. 前言。
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/S0065-230X(22)00012-4
John P O'Bryan, Gary A Piazza
{"title":"Preface.","authors":"John P O'Bryan,&nbsp;Gary A Piazza","doi":"10.1016/S0065-230X(22)00012-4","DOIUrl":"https://doi.org/10.1016/S0065-230X(22)00012-4","url":null,"abstract":"","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"xiii-xiv"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39876001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Chinese herbal medicine on lung disease: an updated review 中药对肺部疾病的作用:最新综述
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522027
Virender Kumar, Davinder Kumar, N. Khatri, Ashwani Kumar, Joginder Khurana
{"title":"Effect of Chinese herbal medicine on lung disease: an updated review","authors":"Virender Kumar, Davinder Kumar, N. Khatri, Ashwani Kumar, Joginder Khurana","doi":"10.53388/2022522027","DOIUrl":"https://doi.org/10.53388/2022522027","url":null,"abstract":"","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90395638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Autophagy-associated long non-coding RNA signature for lung adenocarcinoma 肺腺癌自噬相关的长链非编码RNA特征
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522003
Yufeng Huang, Jing Xiang, Chun Yuan, B. Deng, Xia Yang, Lianxiang Luo, Zhuoyuan Liang
{"title":"Autophagy-associated long non-coding RNA signature for lung adenocarcinoma","authors":"Yufeng Huang, Jing Xiang, Chun Yuan, B. Deng, Xia Yang, Lianxiang Luo, Zhuoyuan Liang","doi":"10.53388/2022522003","DOIUrl":"https://doi.org/10.53388/2022522003","url":null,"abstract":"","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88248769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pandemic adaptation in oncological management-a tertiary care radiation oncology center experience 肿瘤管理中的大流行适应——三级护理放射肿瘤中心经验
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522004
Dillip Kumar, Sanjeev Kumar, A. Amritt, M. Mishra, Poornima Devi, S. Kumar
{"title":"Pandemic adaptation in oncological management-a tertiary care radiation oncology center experience","authors":"Dillip Kumar, Sanjeev Kumar, A. Amritt, M. Mishra, Poornima Devi, S. Kumar","doi":"10.53388/2022522004","DOIUrl":"https://doi.org/10.53388/2022522004","url":null,"abstract":"","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"111 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79203149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
1,3,4-Oxadiazole as an emerging telomerase inhibitor - a promising anticancer motif 1,3,4-恶二唑作为一种新兴的端粒酶抑制剂-一种有前景的抗癌基序
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522018
Davinder Kumar, Virender Kumar, H. Kumar, A. Deep, Rakesh Kumar
{"title":"1,3,4-Oxadiazole as an emerging telomerase inhibitor - a promising anticancer motif","authors":"Davinder Kumar, Virender Kumar, H. Kumar, A. Deep, Rakesh Kumar","doi":"10.53388/2022522018","DOIUrl":"https://doi.org/10.53388/2022522018","url":null,"abstract":"","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"131 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76152066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Matricellular proteins in intrahepatic cholangiocarcinoma. 肝内胆管癌的基质细胞蛋白。
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.01.010
Alphonse E Sirica
{"title":"Matricellular proteins in intrahepatic cholangiocarcinoma.","authors":"Alphonse E Sirica","doi":"10.1016/bs.acr.2022.01.010","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.01.010","url":null,"abstract":"<p><p>Intrahepatic cholangiocarcinoma (iCCA) is typically characterized by a prominent desmoplastic stroma that is often the most dominant feature of the tumor. This tumor reactive stroma is comprised of a dense fibro-collagenous-enriched extracellular matrix (ECM) surrounding the cancer cells, together with other ECM proteins/peptides, specifically secreted matricellular glycoproteins and proteolytic enzymes, growth factors, and cytokines. Moreover, as enjoined by cholangiocarcinoma cells, this enriched tumor microenvironment is populated by various stromal cell types, most prominently, cancer-associated myofibroblasts (CAFs), along with variable numbers of tumor-associated macrophages (TAMs), inflammatory and vascular cell types. While it is now well appreciated that the interplay between cholangiocarcinoma cells, CAFs, and TAMs in particular play a critical role in promoting cholangiocarcinoma progression, therapeutic resistance, and immune evasion, it is also becoming increasingly evident that over-expression and secretion into the tumor microenvironment of functionally overlapping matricellular glycoproteins, including periostin, osteopontin, tenascin-C, thrombospondin-1, mesothelin and others have an important role to play in regulating or modulating a variety of pro-oncogenic cellular functions, including cholangiocarcinoma cell proliferation, invasion, and metastasis, epithelial-mesenchymal transition, ECM remodeling, and immune evasion. Matricellular proteins have also shown promise as potential prognostic factors for iCCA and may provide unique therapeutic opportunities particularly in relation to targeting iCCA pre-metastatic and metastatic niches, tumor cell dormancy, and immune evasion. This review will highlight timely research and its translational implications for salient matricellular proteins in terms of their structure-function relationships, as modulators of intrahepatic cholangiocarcinoma microenvironment and progression, and potential clinical value for iCCA prognosis and therapy.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"249-281"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Inhibition of SHP2 as an approach to block RAS-driven cancers. 抑制SHP2作为阻断ras驱动癌症的途径。
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2021-08-03 DOI: 10.1016/bs.acr.2021.07.002
Yu-Ting Chou, Trever G Bivona
{"title":"Inhibition of SHP2 as an approach to block RAS-driven cancers.","authors":"Yu-Ting Chou,&nbsp;Trever G Bivona","doi":"10.1016/bs.acr.2021.07.002","DOIUrl":"https://doi.org/10.1016/bs.acr.2021.07.002","url":null,"abstract":"<p><p>The non-receptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) is a critical component of RAS/MAPK signaling by acting upstream of RAS to promote oncogenic signaling and tumor growth. Over three decades, SHP2 was considered \"undruggable\" because enzymatic active-site inhibitors generally showed off-target inhibition of other proteins and low membrane permeability. More recently, allosteric SHP2 inhibitors with striking inhibitory potency have been developed. These small molecules effectively block the signal transduction between receptor tyrosine kinases (RTKs) and RAS/MAPK signaling and show efficacy in preclinical cancer models. Moreover, clinical evaluation of these allosteric SHP2 inhibitors is ongoing. RAS proteins which harbor transforming properties by gain-of-function mutations are present in various cancer types. While inhibitors of KRASG12C show early clinical promise, resistance remains a challenge and other forms of oncogenic RAS remain to be selectively inhibited. Here, we summarize the role of SHP2 in RAS-driven cancers and the therapeutic potential of allosteric SHP2 inhibitors as a strategy to block RAS-driven cancers.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"205-236"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39875539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Targeting the "undruggable" RAS with biologics. 用生物制剂靶向 "不可药用 "的 RAS。
2区 医学
Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2021-08-13 DOI: 10.1016/bs.acr.2021.07.006
Michael Whaby, Imran Khan, John P O'Bryan
{"title":"Targeting the \"undruggable\" RAS with biologics.","authors":"Michael Whaby, Imran Khan, John P O'Bryan","doi":"10.1016/bs.acr.2021.07.006","DOIUrl":"10.1016/bs.acr.2021.07.006","url":null,"abstract":"<p><p>RAS proteins represent critical drivers of tumor development and thus are the focus of intense efforts to pharmacologically inhibit these proteins in human cancer. Although recent success has been attained in developing clinically efficacious inhibitors to KRAS<sup>G12C</sup>, there remains a critical need for developing approaches to inhibit additional mutant RAS proteins. A number of anti-RAS biologics have been developed which reveal novel and potentially therapeutically targetable vulnerabilities in oncogenic RAS. This review will discuss the growing field of anti-RAS biologics and potential development of these reagents into new anti-RAS therapies.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"237-266"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627686/pdf/nihms-1843355.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39875997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信